BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25117468)

  • 1. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.
    Ichiki T; Schirger JA; Huntley BK; Brozovich FV; Maleszewski JJ; Sandberg SM; Sangaralingham SJ; Park SJ; Burnett JC
    J Mol Cell Cardiol; 2014 Oct; 75():199-205. PubMed ID: 25117468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure.
    Kuhn M; Voss M; Mitko D; Stypmann J; Schmid C; Kawaguchi N; Grabellus F; Baba HA
    Cardiovasc Res; 2004 Nov; 64(2):308-14. PubMed ID: 15485690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis.
    Ichiki T; Boerrigter G; Huntley BK; Sangaralingham SJ; McKie PM; Harty GJ; Harders GE; Burnett JC
    Am J Physiol Regul Integr Comp Physiol; 2013 Jan; 304(2):R102-9. PubMed ID: 23152112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors.
    Springer J; Azer J; Hua R; Robbins C; Adamczyk A; McBoyle S; Bissell MB; Rose RA
    J Mol Cell Cardiol; 2012 May; 52(5):1122-34. PubMed ID: 22326431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device.
    Bruggink AH; de Jonge N; van Oosterhout MF; Van Wichen DF; de Koning E; Lahpor JR; Kemperman H; Gmelig-Meyling FH; de Weger RA
    J Heart Lung Transplant; 2006 Feb; 25(2):174-80. PubMed ID: 16446217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis.
    Ellmers LJ; Knowles JW; Kim HS; Smithies O; Maeda N; Cameron VA
    Am J Physiol Heart Circ Physiol; 2002 Aug; 283(2):H707-14. PubMed ID: 12124219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natriuretic peptide system in the human retina.
    Rollín R; Mediero A; Roldán-Pallarés M; Fernández-Cruz A; Fernández-Durango R
    Mol Vis; 2004 Jan; 10():15-22. PubMed ID: 14737067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.
    Dickey DM; Potter LR
    J Mol Cell Cardiol; 2011 Jul; 51(1):67-71. PubMed ID: 21459096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natriuretic peptide pathways in heart failure: further therapeutic possibilities.
    Sangaralingham SJ; Kuhn M; Cannone V; Chen HH; Burnett JC
    Cardiovasc Res; 2023 Feb; 118(18):3416-3433. PubMed ID: 36004816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart specific up-regulation of genes for B-type and C-type natriuretic peptide receptors in diabetic mice.
    Christoffersen C; Bartels ED; Nielsen LB
    Eur J Clin Invest; 2006 Feb; 36(2):69-75. PubMed ID: 16436087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart.
    Li Y; Kishimoto I; Saito Y; Harada M; Kuwahara K; Izumi T; Takahashi N; Kawakami R; Tanimoto K; Nakagawa Y; Nakanishi M; Adachi Y; Garbers DL; Fukamizu A; Nakao K
    Circulation; 2002 Sep; 106(13):1722-8. PubMed ID: 12270869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte.
    Dickey DM; Dries DL; Margulies KB; Potter LR
    J Mol Cell Cardiol; 2012 Mar; 52(3):727-32. PubMed ID: 22133375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.
    Dickey DM; Flora DR; Bryan PM; Xu X; Chen Y; Potter LR
    Endocrinology; 2007 Jul; 148(7):3518-22. PubMed ID: 17412809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
    Nakanishi M; Saito Y; Kishimoto I; Harada M; Kuwahara K; Takahashi N; Kawakami R; Nakagawa Y; Tanimoto K; Yasuno S; Usami S; Li Y; Adachi Y; Fukamizu A; Garbers DL; Nakao K
    Hypertension; 2005 Aug; 46(2):441-7. PubMed ID: 15998711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and functional expression of the natriuretic peptide system in human lens epithelial cells.
    Cammarata PR; Braun B; Dimitrijevich SD; Pack J
    Mol Vis; 2010 Apr; 16():630-8. PubMed ID: 20700369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential gene expression of the three natriuretic peptides and natriuretic peptide receptor subtypes in human liver.
    Vollmar AM; Paumgartner G; Gerbes AL
    Gut; 1997 Jan; 40(1):145-50. PubMed ID: 9155593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.
    Dickey DM; Barbieri KA; McGuirk CM; Potter LR
    Mol Pharmacol; 2010 Sep; 78(3):431-5. PubMed ID: 20530652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.
    Potter LR
    Pharmacol Ther; 2011 Apr; 130(1):71-82. PubMed ID: 21185863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts.
    Chen Y; Zheng Y; Iyer SR; Harders GE; Pan S; Chen HH; Ichiki T; Burnett JC; Sangaralingham SJ
    J Mol Cell Cardiol; 2019 May; 130():140-150. PubMed ID: 30954448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.
    Lok SI; Nous FM; van Kuik J; van der Weide P; Winkens B; Kemperman H; Huisman A; Lahpor JR; de Weger RA; de Jonge N
    Eur J Cardiothorac Surg; 2015 Sep; 48(3):407-15. PubMed ID: 25609773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.